· News

POELLATH advises CEO of Neuraxpharm on sale to Permira

The private equity investor Permira has acquired Neuraxpharm Group (“Neuraxpharm”) from funds managed by Apax. The transaction volume is undisclosed.The transaction is still subject to the consent of the antitrust authorities.

Neuraxpharm is headquartered in Langenfeld/Rheinland and was founded in 1985. Today the company employs 850 people with an annual turnover of more than EUR 460 million. The company specializes in pharmaceuticals to treat diseases of the central nervous system (CNS), operates in 13 countries and today covers 80% of the European CNS pharmaceuticals market. Neuraxpharm is a leader for the development and marketing of high-quality medications and healthcare products for chronic patients that suffer from neurological and psychiatric illnesses like epilepsy, Parkinson’s, Alzheimer’s, depression and psychoses. It is one of the fastest growing specialty pharmaceutical companies in Europe.

POELLATH comprehensively advised the CEO and other managers on all tax matters and on the management participation program with the following team:

Monika Goede
+49 (89) 24 24 0 - 228 call